UROGEN PHARMA LTD.

(URGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

HC Wainwright Adjusts UroGen Pharma's Price Target to $34 From $50, Reiterates Buy Rating

01/18/2022 | 10:43am EDT


© MT Newswires 2022
All news about UROGEN PHARMA LTD.
05/18UroGen Pharma to Present at Upcoming Investor Conferences
BU
05/17UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Off..
AQ
05/16UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Off..
BU
05/16UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association..
AQ
05/13UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association..
BU
05/10TRANSCRIPT : UroGen Pharma Ltd., Q1 2022 Earnings Call, May 10, 2022
CI
05/10UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Develop..
BU
05/10UROGEN PHARMA LTD. Management's Discussion and Analysis of Financial Condition and Res..
AQ
05/10UroGen Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10Earnings Flash (URGN) UROGEN PHARMA Posts Q1 Loss $-1.25, vs. Street Est of $-1.25
MT
More news
Analyst Recommendations on UROGEN PHARMA LTD.
More recommendations
Financials (USD)
Sales 2022 76,8 M - -
Net income 2022 -114 M - -
Net cash 2022 31,0 M - -
P/E ratio 2022 -1,14x
Yield 2022 -
Capitalization 125 M 125 M -
EV / Sales 2022 1,22x
EV / Sales 2023 0,81x
Nbr of Employees 192
Free-Float 91,1%
Chart UROGEN PHARMA LTD.
Duration : Period :
UroGen Pharma Ltd. Technical Analysis Chart | URGN | IL0011407140 | MarketScreener
Technical analysis trends UROGEN PHARMA LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 5,51 $
Average target price 24,33 $
Spread / Average Target 342%
EPS Revisions
Managers and Directors
Elizabeth Barrett President, Chief Executive Officer & Director
Dong Kim Chief Financial & Accounting Officer
Arie S. Belldegrun Chairman
Moran Mieron Director-Research & Pre-Clinical Affairs
Mark P. Schoenberg Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
UROGEN PHARMA LTD.-42.06%125
GILEAD SCIENCES, INC.-12.33%79 850
REGENERON PHARMACEUTICALS, INC.7.98%73 473
VERTEX PHARMACEUTICALS22.20%68 632
WUXI APPTEC CO., LTD.-17.77%42 378
BIONTECH SE-36.69%39 666